Role of Intercellular Adhesion Molecule -1 in Acne Vulgaris patients: Effect of Montelukast therapy

Abdel-Hamid, Soheir; Fouad, Alshayma Gamal; Elsaied, Abdelrahman Abdel-Hamid; Ibrahim, Hassan M.

doi:10.21608/svuijm.2025.347453.2058

	Role of Intercellular Adhesion Molecule -1 in Acne Vulgaris patients: Effect of Montelukast therapy
SVU-International Journal of Medical Sciences
Article 42, Volume 8, Issue 1, January 2025, Page 493-510 PDF (453.52 K)
Document Type: Original research articles
DOI: 10.21608/svuijm.2025.347453.2058
View on SCiNiTO
Authors
Soheir Abdel-Hamid ¹; Alshayma Gamal Fouad¹; Abdelrahman Abdel-Hamid Elsaied²; Hassan M. Ibrahim¹
¹Department of Dermatology, Venereology, and Andrology, Faculty of Medicine, South Valley University, Qena, Egypt.
²Department of Clinical Pathology, Faculty of Medicine, South Valley University, Qena Egypt.
Abstract
Background: Acne vulgaris (AV) is the most common inflammatory skin condition. It has complicated pathophysiology. Objectives: We compared montelukast therapy on AV patients over a three-month period, assessing serum of soluble intercellular adhesion molecule -1 (sICAM-1) in AV, comparing it to a control group and its relationship to AV severity. Patients and method: 40 AV patients were split into two groups based on Investigator's Global Assessment: group 1 was moderate AV, group 2 was severe AV. (sICAM-1) was measured in AV patients before and after montelukast treatment and compared to the control group (group 3). Results: Moderate AV group outperformed the severe group in clinical improvement: moderate AV: good (55%), excellent (30%), severe AV: good (40%), and excellent (20%). Median s.ICAM-1 level was significantly lower in the control group (1.3 [0.5-3]) compared with both (moderate AV (35.5 [15-45]) (p < 0.001) and severe AV (57 [45-78]) (p < 0.001). After treatment, there was a significant difference between the three groups in the median level of s.ICAM-1 (p < 0.001) i.e., the median level was significantly lower in the control group (1.3 [0.5-3]) compared with (moderate AV (12.5 [6-72]) (p < 0.001) and severe AV (54 [39-72]) (p < 0.001). Treatment side effects were significant with severe AV (p = 0.046) compared with moderate AV. Conclusion: The study revealed that AV patients had significantly higher serum levels ( sICAM-1), an independent predictor of acne severity. Montelukast is a safe, efficient treatment for AV, especially moderate.
Keywords
Acne vulgaris; s.ICAM-1; Montelukast


Statistics Article View: 145 PDF Download: 104